Unbalanced alternative splicing and its significance in cancer

BioEssays

Volumn 28, Issue 4, 2006, Pages 378-386

  Venables, Julian P ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; PROTEIN BCL 2; PROTEIN MDMX; PROTEIN P53; PROTEIN P73; VASCULOTROPIN; WNT1 PROTEIN;

ALTERNATIVE RNA SPLICING; ANGIOGENESIS; APOPTOSIS; CANCER; CANCER INVASION; CELL PROLIFERATION; DNA DAMAGE; DNA SYNTHESIS; EXON; GENE EXPRESSION; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; INTRON; LUNG CANCER; METASTASIS; OVARY CARCINOMA; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REVIEW; SQUAMOUS CELL CARCINOMA;

ALTERNATIVE SPLICING; ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS;

EID: 33645833000     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20390     Document Type: Review

References (100)

1. Matlin AJ, Clark F, Smith CW. 2005. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 6:386-398.
2. Cote GJ, Bruno IG, Jin W. 2004. Abnormal Regulation of RNA splicing in gliomas. In: Zhang W, Fuller GN, editors. Genomic and molecular neuro-oncology. Massachusetts: Jones and Bartlett; p 165-183.
3. Kalnina Z, Zayakin P, Silina K, Line A. 2005. Alterations of pre-mRNA splicing in cancer. Genes Chromosomes Cancer 42:342-357.
4. Roy M, Xu Q, Lee C. 2005. Evidence that public database records for many cancer-associated genes reflect a splice form found in tumors and lack normal splice forms. Nucleic Acids Res 33:5026-5033.
5. Song SW, Cote GJ, Wu C, Zhang W. 2002. Alternative Splicing: Genetic Complexity in Cancer. In: Zhang W, Shmulevich I, editors. Computational and statistical approaches to genomics. Boston: Kluwer Academic; p 277-297.
6. Venables JP. 2004. Aberrant and alternative splicing in cancer. Cancer Res 64:7647-7654.
7. Wang L, Duke L, Zhang PS, Arlinghaus RB, Symmans WF, et al. 2003. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63:4724-4730.
8. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, et al. 2002. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res 62:4123-4131.
9. Hu Y, Fang C, Xu Y. 2005. The effect of isoforms of the cell polarity protein, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells. Cell Mol Life Sci 62:1974-1983.
10. Song SW, Fuller GN, Zheng H, Zhang W. 2005. Inactivation of the invasion inhibitory gene IIp45 by alternative splicing in gliomas. Cancer Res 65:3562-3567.
11. Adamia S, Reiman T, Crainie M, Mant MJ, Belch AR, Pilarski LM. 2005. Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma. Blood 105:4836-4844.
12. Maxwell CA, Rasmussen E, Zhan F, Keats JJ, Adamia S, et al. 2004. RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104:1151-1158.
13. Mills AA. 2005. p53: link to the past, bridge to the future. Genes Dev 19: 2091-2099.
14. Cui R, He J, Mei R, de Fromentel CC, Martel-Planche G, et al. 2005. Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem Biophys Res Commun 336:339-345.
15. Arvanitis DA, Lianos E, Soulitzis N, Delakas D, Spandidos DA. 2004. Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncol Rep 12:1131-1137.
16. Nyman U, Sobczak-Pluta A, Vlachos P, Perlmann T, Zhivotovsky B, Joseph B. 2005. Full-length P73alpha represses drug-induced apoptosis in SCLC cells. J Biol Chem 280:34159-34169.
17. Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, et al. 2005. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res 65:1213-1222.
18. Narla G, DiFeo A, Yao S, Banno A, Hod E, et al. 2005. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Res 65:5761-5768.
19. Bartel F, Schulz J, Bohnke A, Blumke K, Kappler M, et al. 2005. Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. Int J Cancer 117:469-475.
20. Li F. 2005. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 92:212-216.
21. Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, et al. 2005. Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer. Br J Cancer 92:120-124.
22. Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. 2005. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 27:1151-1157.
23. Zhu N, Gu L, Findley HW, Li F, Zhou M. 2004. An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene 23:7545-7551.
24. Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, et al. 2002. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer 86:737-743.
25. Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. 2005. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep 13:891-897.
26. Kotoula V, Barbanis S, Nikolakaki E, Koufoyannis D, Papadimitriou CS, Karkavelas G. 2004. Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas. Acta Neuropathol (Berl) 107:443-451.
27. Brambilla C, Folini M, Gandellini P, Daprai L, Daidone MG, Zaffaroni N. 2004. Oligomer-mediated modulation of hTERT alternative splicing induces telomerase inhibition and cell growth decline in human prostate cancer cells. Cell Mol Life Sci 61:1764-1774.
28. van Doom R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. 2002. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 62:5389-5392.
29. Akgul C, Moulding DA, Edwards SW. 2004. Alternative splicing of Bcl-2-related genes: functional consequences and potential therapeutic applications. Cell Mol Life Sci 61:2189-2199.
30. Wu S, Gessner R, Taube T, von Stackelberg A, Henze G, Seeger K. 2005. Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 23:3038-3042.
31. Gaggero A, De Ambrosis A, Mezzanzanica D, Piazza T, Rubartelli A. et al. 2004. A novel isoform of pro-interleukin-18 expressed in ovarian tumors is resistant to caspase-1 and -4 processing. Oncogene 23:7552-7560.
32. Wang HC, Su YR, Han KJ, Pang XW, Peng JR. et al. 2004. Multiple variants and a differential splicing pattern of kinectin in human hepatocellular carcinoma. Biochem Cell Biol 82:321-327.
33. Solier S, Lansiaux A, Logette E, Wu J, Soret J, et al. 2004. Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res 2:53-61.
34. Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. 2005. Implication of alternative splice transcripts of caspase-3 and survivin in chemoresistance. Bull Cancer 92:219-226.
35. Mohr A, Zwacka RM, Jarmy G, Buneker C, Schrezenmeier H, et al. 2005. Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemio cells from CD95-mediated apoptosis. Oncogene 24:2421-2429.
36. Yang Y, Hu W, Feng S, Ma J, Wu M. 2005. RIP3 beta and RIP3 gamma, two novel splice variants of receptor-interacting protein 3 (RIP3), downregulate RIP3-induced apoptosis. Biochem Biophys Res Commun 332:181-187.
37. Bruno IG, Jin W, Cote GJ. 2004. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 13:2409-2420.
38. Jordan P, Brazao R, Boavida MG, Gespach C, Chastre E. 1999. Cloning of a novel human Radb splice variant with increased expression in colorectal tumors. Oncogene 18:6835-6839.
39. Matos P, Collard JG, Jordan P. 2003. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 278:50442-504428.
40. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, et al. 2005. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 436:123-127.
41. Takino T, Nakada M, Miyamori H, Yamashita J, Yamada KM, Sato H. 2003. Crkl adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res 63:2335-2337.
42. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. 2004. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 23:9369-9380.
43. Tsuiki H, Tnani M, Okamoto I, Kenyon LC, Emlet DR. et al. 2003. Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors. Cancer Res 63:250-255.
44. Sato S, Idogawa M, Honda K, Fujii G, Kawashima H, et al. 2005. beta-Catenin Interacts With the FUS Proto-oncogene Product and Regulates Pre-mRNA Splicing. Gastroenterology 129:1225-1236.
45. Howng SL, Huang FH, Hwang SL, Lieu AS, Sy WD, et al. 2004. Differential expression and splicing isoform analysis of human Tcf-4 transcription factor in brain tumors. Int J Oncol 25:1685-1692.
46. Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, et al. 2001. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene 20:5525-5532.
47. Hellmich MR, Rui XL, Hellmich HL, Fleming RY, Evers BM, Townsend CM Jr. 2000. Human colorectal cancers express a constitutively active cholecystokinin-B/gastrin receptor that stimulates cell growth. J Biol Chem 275:32122-32128.
48. Chao C, Ives KL, Goluszko E, Kolokoltsov AA, Davey RA, et al. 2005. SRC regulates constitutive internalization and rapid resensitization of a CCK2 receptor splice variant. J Biol Chem 280:33368-33373.
49. Olszewska-Pazdrak B1 Townsend CM Jr, Hellmich MR. 2004. Agonist-independent activation of Src tyrosine kinase by a cholecystokinin-2 (CCK2) receptor splice variant. J Biol Chem 279:40400-40404.
50. Ebbinghaus C, Scheuermann J, Neri D, Elia G. 2004. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des 10:1537-1549.
51. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, et al. 2004. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64: 7822-7835.
52. Cui TG, Foster RR, Saleem M, Mathieson PW, Gillatt DA, et al. 2004. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b rpar; mRNA and protein. Am J Physiol Renal Physiol 286: F767-F773.
53. Bates DO, Harper SJ. 2005. Therapeutic potential of inhibitory VEGF splice variants. Future Oncology 1:467-473.
54. Garcia-Blanco MA. 2005. Making antisense of splicing. Curr Opin Mol Ther 7:476-482.
55. Koduri S, Goldhar AS, Vonderhaar BK. 2005. Activation of vascular endothelial growth factor (VEGF) by the ER-alpha variant, ERDelta3. Breast Cancer Res Treat.
56. Stearns ME, Wang M, Hu Y, Kim G, Garcia FU. 2004. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest 84:785-795.
57. Harris H. 2005. A long view of fashions in cancer research. Bioessays 27:833-838.
58. Jang JH, Shin KH, Park YJ, Lee RJ, MoKeehan WL, Park JG. 2000. Novel transcripts of fibroblast growth factor receptor 3 reveal aberrant splicing and activation of cryptic splice sequences in colorectal cancer. Cancer Res 60:4049-4052.
59. Sturla LM, Merrick AE, Burchill SA. 2003. FGFR3IIIS: a novel soluble FGFR3 spliced variant that modulates growth is frequently expressed in tumour cells. Br J Cancer 89:1276-1284.
60. Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, et al. 2004. TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6:347-360.
61. Mochizuki H, Nishi T, Bruner JM, Lee PS, Levin VA, Saya H. 1992. Alternative splicing of neurofibromatosis type 1 gene transcript in malignant brain tumors: PCR analysis of frozen-section mRNA. Mol Carcinog 6:83-87.
62. Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. 2002. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254.
63. Zhu X, Daffada AA, Chan CM, Dowsett M. 1997. Identification of an exon 3 deletion splice variant androgen receptor mRNA in human breast cancer. Int J Cancer 72:574-580.
64. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA. 1997. Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 15:3059-3065.
65. Coulson JM, Edgson JL, Woll PJ, Quinn JP. 2000. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 60:1840-1844.
66. Relogio A, Ben-Dov C, Baum M, Ruggiu M, Gemund C, et al. 2005. Alternative splicing microarrays reveal functional expression of neuron-specific regulators in Hodgkin lymphoma cells. J Biol Chem 280:4779-4784.
67. Goodman PA, Wood CM, Vassilev A, Mao C, Uckun FM. 2001. Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia. Oncogene 20:3969-3978.
68. Jumaa H, Bossaller L, Portugal K, Storch B, Lotz M, et al. 2003. Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic leukaemia. Nature 423:452-456.
69. Klein F, Feldhahn N, Harder L, Wang H, Wartenberg M, et al. 2004. The BCR-ABL1 kinase bypasses selection for the expression of a pre-B cell receptor in pre-B acute lymphoblastic leukemia cells. J Exp Med 199:673-685.
70. Feldhahn N, Rio P, Soh BN, Liedtke S, Sprangers M, et al. 2005. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci USA 102:13266-13271.
71. Feldhahn N, Klein F, Mooster JL, Hadweh P, Sprangers M, et al. 2005. Mimicry of a constitutively active pre-B cell receptor in acute lymphoblastic leukemia cells. J Exp Med 201:1837-1852.
72. Salesse S, Dylla SJ, Verfaillie CM. 2004. p210BCR/ABL-induced alteration of pre-mRNA splicing in primary human CD34+ hematopoietic progenitor cells. Leukemia 18:727-733.
73. Klein F, Feldhahn N, Herzog S, Sprangers M, Mooster JL, et al. 2005. BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. Oncogene.
74. Takanashi M, Yagi T, Imamura T, Tabata Y, Morimoto A, et al. 2002. Expression of the Ikaros gene family in childhood acute lymphoblastic leukaemia. Br J Haematol 117:525-530.
75. Sun L, Heerema N, Crotty L, Wu X, Navara C, et al. 1999. Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. Proc Natl Acad Sci USA 96:680-685.
76. Theoleyre O, Baklouti F. 2004. Oncogenic transcription factors as splicing regulators. Med Sci (Paris) 20:1014-1019.
77. Knoop LL, Baker SJ. 2001. EWS/FLI alters 5′-splice site selection. J Biol Chem 276:22317-22322.
78. Chansky HA, Hu M, Hickstein DD, Yang L. 2001. Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. Cancer Res 61:3586-3590.
79. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. 2005. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 5:615-625.
80. Venables JP. 2002. Alternative splicing in the testes. Curr Opin Genet Dev 12:615-619.
81. Kan Z, Garrett-Engele PW, Johnson JM, Castle JC. 2005. Evolutionary conserved and diverged alternative splicing events show different expression and functional profiles. Nucleic Acids Res 33:5659-5666.
82. Okumura M, Kondo S, Ogata M, Kanemoto S, Murakami T, et al. 2005. Candidates for tumor-specific alternative splicing. Biochem Biophys Res Commun 334:23-29.
83. Kirschbaum-Slager N, Parmigiani RB, Camargo AA, de Souza SJ. 2005. Identification of human exons overexpressed in tumors through the use of genome and expressed sequence data. Physiol Genomics 21:423-432.
84. Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ. 2004. Splicing factors are differentially expressed in tumors. Genet Mol Res 3:512-5120.
85. Schenk PW, Stoop H, Bokemeyer C, Mayer F, Stoter G, et al. 2004. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia 6:297-301.
86. Sanz G, Mir L, Jacquemin-Sablon A. 2002, Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene. Cancer Res 62:4453-4458.
87. He X, Ee PL, Coon JS, Beck WT. 2004. Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20. Clin Cancer Res 10:4652-4660.
88. Zerbe LK, Pino I, Pio R, Cosper PF, Dwyer-Nield LD, et al. 2004. Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog 41:187-196.
89. Patry C, Bouchard L, Labrecque P, Gendron D, Lemieux B, et al. 2003. Small interfering RNA-mediated reduction in heterogeneous nuclear ribonucleoparticule A1/A2 proteins induces apoptosis in human cancer cells but not in normal mortal cell lines. Cancer Res 63:7679-7688.
90. Li X, Manley JL. 2005. Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122:365-378.
91. Li X, Wang J, Manley JL. 2005. Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev 19:2705-2714.
92. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, et al. 2005. Cell Motility Is Controlled by SF2/ASF through Alternative Splicing of the Ron Protooncogene. Mol Cell 20:881-890.
93. Cheng C, Sharp PA. 2006. Regulation of CD44 Alternative Splicing by SRm160 and Its Potential Role in Tumor Cell Invasion. Mol Cell Biol 26: 362-370.
94. Hayes GM, Dougherty ST, Davis PD, Dougherty GJ. 2004. Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expression. Cancer Gene Ther 11:797-807.
95. Galiana-Arnoux D, Gatto-Konczak FD, Gesnel MC, Breathnach R. 2005. Intronic UGG repeats coordinate splicing of CD44 alternative exons v8 and v9. Biochem Biophys Res Commun 336:667-673.
96. Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R. 2005. CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. Cancer Res 65:5812-5817.
97. Dall P, Herrmann I, Durst B, Stoff-Khalili MA, Bauerschmitz G, et al. In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells. Cancer Immunol Immunother 54:51-60.
98. Fehlbaum P, Guihal C, Bracco L, Cochet O. 2005. A microarray configuration to quantify expression levels and relative abundance of splice variants. Nucleic Acids Res 33:e47.
99. Ule J, Ule A, Spencer J, Williams A, Hu JS, et al. 2005. Nova regulates brain-specific splicing to shape the synapse. Nat Genet 37:844-852.
100. Watahiki A, Waki K, Hayatsu N, Shiraki T, Kondo S, et al. 2004. Libraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas. Nat Methods 1:233-239.